{"id":"NCT04910165","sponsor":"St. Luke's Hospital, Pennsylvania","briefTitle":"Exparel Use in Adductor Canal Block After Total Knee Arthroplasty","officialTitle":"Adductor Canal Blocks Using Exparel for Pain Control After Total Knee Arthroplasty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-01","primaryCompletion":"2021-09-15","completion":"2021-10-15","firstPosted":"2021-06-02","resultsPosted":"2022-05-20","lastUpdate":"2022-05-20"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis Knee","Pain, Postoperative","Opioid Use"],"interventions":[{"type":"DRUG","name":"Exparel","otherNames":[]},{"type":"DRUG","name":"Ropivacaine","otherNames":[]}],"arms":[{"label":"Exparel","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.","primaryOutcome":{"measure":"Hospital Length of Stay","timeFrame":"Through entire inpatient hospital stay (lasted from 1 day to 1 week)","effectByArm":[{"arm":"Exparel","deltaMin":36.3,"sd":12.4},{"arm":"Control","deltaMin":49.7,"sd":35.3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Nausea and Vomiting"]}}